Johnson & Johnson, the embattled drug manufacturer, increased its lobbying efforts significantly over 2009. In fact, the company increased its expenditures by over 40% - from $1.7 million in third quarter 2009 to $2.4 million in third quarter 2010.
As the company has recalled dozens of products, it has faced two Congressional hearings over its actions. J&J seems to hope that increased attention to politicians will help it avoid a Consent Decree and additional future scrutiny.
